Evidence-based recommendations for the use of antiemetics in radiotherapy

Keyphrases

• Radiotherapy 100%
• Radiotherapy-induced 100%
• Antiemetics 100%
• Evidence-based Recommendations 100%
• Emesis 100%
• Multinational Association of Supportive Care in Cancer 100%
• High Risk 66%
• Cranium 66%
• 5-HT3 Antagonist 66%
• Minimal Risk 66%
• Clinical Practice 33%
• Breast 33%
• Total Body Irradiation 33%
• Dopamine 33%
• Head-and-neck 33%
• Pelvis 33%
• Risk Level 33%
• Radiosurgery 33%
• Moderate Risk 33%
• Chemotherapy-induced 33%
• Thorax 33%
• International Consensus Conference 33%
• Guideline Development 33%
• Lower Neck 33%
• Pertinent Information 33%
• Steering Committee 33%
• 5-HT3 Receptor Antagonist 33%
• American Society of Clinical Oncology 33%
• Upper Abdomen 33%
• Craniospinal 33%
• Low Head 33%
• Reporting Recommendations 33%
• Low-risk Group 33%

Medicine and Dentistry

• Antiemetic 100%
• Radiation Therapy 100%
• Malignant Neoplasm 50%
• Supportive Care 50%
• 5-HT3 Antagonist 50%
• Pelvis 16%
• Whole Body Radiation 16%
• Radiosurgery 16%
• Low Risk Population 16%
• Neck 16%
• Clinical Oncology 16%
• Dexamethasone 16%